Logiscreen

Insulet Corporation

$153.22
Market Cap 10.79B
ROE 21.4%
Gross Margin 69.4%
Debt/Equity 0.7
Current Ratio 2.5
Revenue QoQ 33.9%
EPS QoQ 1.6%
F-Score 6

About

Insulet Corporation, headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the tubeless disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s flagship innovation, the Omnipod 5 Automated Insulin Delivery System, integrates with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and can be controlled by a compatible personal smartphone in the U.S. or by the Omnipod 5 Controller. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical Devices

Sector context

Healthcare

Fair Value

Trading at a discount to sector peers

P/E
34.04
vs median 33.61
P/B
7.91
vs median 2.16
ROE
0.21
vs median 0.09

Decent quality with acceptable fundamentals

Large-cap company with established market presence

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics